Disclosure filings show that Representative Kevin Hern sold his entire UnitedHealth position on December 23, 2025, in a transaction valued between $250,001 and $500,000. The sale was reported on January 22, 2026, as a ‘sell to close,’ confirming a complete exit. At the time of the transaction, UnitedHealth shares were trading near their lowest levels of the year, following a volatile period driven by margin compression in the Medicare Advantage business and regulatory uncertainty. Hern, who sits on the House Ways and Means Subcommittee on Health, had accumulated the position over 12 separate purchases between October 2021 and July 2024 but made no partial dispositions during periods of relative strength, leaving the stake underwater at the time of sale.

In 2025, UnitedHealth faced sharply rising medical costs that drove Medicare Advantage margins down by an estimated 150 basis points year-over-year. The company withdrew its full-year guidance in September after reporting a 7% decline in operating earnings for the third quarter. Management upheaval, including the abrupt departure of the chief financial officer and two regional vice presidents, exacerbated investor concerns about execution and cost controls. Insurer medical expense ratios climbed to 83.2%, up from 81.1% the prior year, reflecting increased patient utilization and strained provider networks. These pressures contributed to a 14% drop in the stock price from January through November 2025.

On January 20, 2026, the Federal Trade Commission announced a 14-day suspension of its administrative case against major pharmacy benefit managers, including UnitedHealth’s OptumRx unit. The stay postpones discovery deadlines and delays the evidentiary hearing until July 1, 2026, while settlement negotiations appear to be underway. Originally filed in September 2024, the case alleges anti-competitive practices and inflated list prices for insulin and specialty generics. The temporary pause follows a separate FTC staff report that identified markups exceeding 200% on certain oncology and HIV treatments, and a recent political spotlight on PBM rebate structures. Investors view the delay as a positive, reducing near-term legal overhang and allowing focus on core margin recovery initiatives.